Thrive Earlier Detection logo

Thrive Earlier Detection Funding & Investors

A cancer diagnosis is something no one wants to hear. Too often, cancer is detected late, once it has spread and treatment options are limited. But cancer can be more effectively treated with an intent to cure if caught in the earlier stages. At Thrive, an Exact Sciences Company, our goal is to transform this outlook: to catch cancer earlier, including several with no screening options today, to improve patient outcomes. We are developing a blood-based test that is designed to be affordable and utilized as part of routine medical care to detect multiple types of cancer at earlier stages. Our approach goes beyond a cancer diagnosis. We are developing a platform that will serve as a resource to help patients and their families maneuver the often confusing and overwhelming path that follows a cancer diagnosis.

thrivedetect.com

Total Amount Raised: $367,000,000

Thrive Earlier Detection Funding Rounds

  • Series B

    $257,000,000

    Series B Investors

    Casdin Capital
    Section 32
    Intermountain Ventures
    Bain Capital Life Sciences
    Rock Springs Capital
    Moore Strategic Ventures
    Brown Advisory
    Perceptive Advisors
    T. Rowe Price
    Driehaus Capital Management
    Henderson Global Investors
    Lux Capital
    Sands Capital Ventures
    Invus
    Third Rock Ventures
    The Blue Venture Fund
    Gamma3
    Camden Partners
    Cowin Venture
    Biomatics Capital Partners
    Exact Sciences
  • Series A

    $110,000,000

    Series A Investors

    Third Rock Ventures
    Biomatics Capital Partners
    The Blue Venture Fund
    Section 32
    Invus
    Casdin Capital
    Camden Partners
    Gamma3
    Exact Sciences
    Cowin Venture
Funding info provided by Diffbot.